BIORIDIS Srl, Via Alfonso Rubbiani, 5, Bologna (BO) CAP 40124

presso TLS, Via Str. del Petriccio e Belriguardo, 35, 53100 Siena

Italia

BIORIDIS Srl

Cap. sociale 10.000€ i.v.

P.IVA 03514131204

• Home
• About us
  • Vision
  • Team
  • Collaboration
• LIVELMIA Technology
• LIVELMIA kit
• QE-AMR
• LIVELMIA platform
• O-GenSI
• News
• Contacts

O-GenSi (Oligo for gene silencing)
BIORIDIS your reliable partner for gene silencing

Thanks to years of experience in oligo design and synthesis, BIORIDIS offers a custom-made service for the design and production of oligo-PNAs (peptide nucleic acids) for gene silencing: O-GenSi.

BIORIDIS support in the design of the best oligos using the Gen-LIVELMIA software for gene silencing. BIORIDIS support in the use of oligos for your studies.

O-GenSi advantage in gene silencing:

High chemical and biological stability: resistance to chemical and enzymatic degradation (proteases, nucleases)¹.

 High specificity and affinity: ability to target mRNA, ncRNA and miRNA also distinguishing isomiRs and pre-miRs, antigene approach^2-3.

Easy-of use: no need for electroporation or other chemical system for cell delivery^2-3.

 

Reference.

1. Application of peptide nucleic acid in cancer therapy. Knudsen H, Nielsen PE. Anticancer Drugs. 1997 Feb;8(2):113-8. doi: 10.1097/00001813-199702000-00002. PMID: 9073307 Review.

2. Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy. Tonelli R, … , Shipley J. Clin Cancer Res. 2012 Feb 1;18(3):796-807. doi: 10.1158/1078-0432.CCR-11-1981. Epub 2011 Nov 7. PMID: 22065083.

3. Peptide nucleic acid (PNA) and its applications in chemical biology, diagnostics, and therapeutics. Saarbach J, Sabale PM, Winssinger N. Curr Opin Chem Biol. 2019 Oct;52:112-124. doi: 10.1016/j.cbpa.2019.06.006. Epub 2019 Sep 18. PMID: 31541865 Review.